2025
Connectome-based predictive modeling of early and chronic psychosis symptoms
Foster M, Ye J, Powers A, Dvornek N, Scheinost D. Connectome-based predictive modeling of early and chronic psychosis symptoms. Neuropsychopharmacology 2025, 1-9. PMID: 40016363, DOI: 10.1038/s41386-025-02064-9.Peer-Reviewed Original ResearchConnectome-based predictive modelingPositive and Negative Syndrome ScalePsychosis symptomsSymptom networksSymptom severityBrain networksNeural correlates of CPResting-state functional magnetic resonance imagingFunctional magnetic resonance imagingNegative Syndrome ScaleIdentified group differencesPredicted effect sizeCorrelates of CPGeneral psychopathologyNegative symptomsPositive symptomsSyndrome ScaleFrontoparietal networkNeural correlatesVirtual lesion analysisGroup differencesConnectivity changesEffect sizeLesion analysisLongitudinal studyA generalized reward processing deficit pathway to negative symptoms across diagnostic boundaries
Spilka M, Millman Z, Waltz J, Walker E, Levin J, Powers A, Corlett P, Schiffman J, Gold J, Silverstein S, Ellman L, Mittal V, Woods S, Zinbarg R, Strauss G. A generalized reward processing deficit pathway to negative symptoms across diagnostic boundaries. Psychological Medicine 2025, 55: e6. PMID: 39901872, DOI: 10.1017/s003329172400326x.Peer-Reviewed Original ResearchConceptsNegative symptomsDiagnostic boundariesPsychiatric diagnosisTransdiagnostic sample of youthProcessing profilesEffort-cost computationsPositive valence systemsElevated negative symptomsHelp-seeking participantsClinical high riskClinical group membershipSample of youthHedonic reactivityTransdiagnostic sampleCHR criteriaNeurobiological mechanismsPsychosis riskSubgroup of participantsBehavioral tasksClinical interviewPsychiatric disordersClinical participantsValence systemsGroup membershipDiagnostic classificationRevisiting the Defeatist Performance Belief Scale in Adults With Schizophrenia and Youth at Clinical High-Risk for Psychosis: A Comprehensive Psychometric Analysis
Luther L, Ahmed A, Grant P, Granholm E, Gold J, Williams T, Pratt D, Holden J, Walker E, Arnold L, Ellman L, Mittal V, Zinbarg R, Silverstein S, Corlett P, Powers A, Woods S, Waltz J, Schiffman J, Strauss G. Revisiting the Defeatist Performance Belief Scale in Adults With Schizophrenia and Youth at Clinical High-Risk for Psychosis: A Comprehensive Psychometric Analysis. Schizophrenia Bulletin 2025, sbae220. PMID: 39749462, DOI: 10.1093/schbul/sbae220.Peer-Reviewed Original ResearchDefeatist performance beliefsSchizophrenia spectrum groupClinical high riskNegative symptomsFactor structureCognitive model of negative symptomsMechanisms of negative symptomsModel of negative symptomsNegative symptom improvementNegative symptoms treatmentPhase of psychosisFactor analysisComprehensive psychometric analysisConfirmatory factor analysisExploratory factor analysisPositive symptomsCHR samplesPerformance beliefsMeasurement invarianceDiscriminant validityConvergent validityPsychometric propertiesCognitive modelUnidimensional modelBeliefs Scale
2024
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
Wannan C, Nelson B, Addington J, Allott K, Anticevic A, Arango C, Baker J, Bearden C, Billah T, Bouix S, Broome M, Buccilli K, Cadenhead K, Calkins M, Cannon T, Cecci G, Chen E, Cho K, Choi J, Clark S, Coleman M, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Dwyer D, Ebdrup B, Ellman L, Fusar-Poli P, Galindo L, Gaspar P, Gerber C, Glenthøj L, Glynn R, Harms M, Horton L, Kahn R, Kambeitz J, Kambeitz-Ilankovic L, Kane J, Kapur T, Keshavan M, Kim S, Koutsouleris N, Kubicki M, Kwon J, Langbein K, Lewandowski K, Light G, Mamah D, Marcy P, Mathalon D, McGorry P, Mittal V, Nordentoft M, Nunez A, Pasternak O, Pearlson G, Perez J, Perkins D, Powers A, Roalf D, Sabb F, Schiffman J, Shah J, Smesny S, Spark J, Stone W, Strauss G, Tamayo Z, Torous J, Upthegrove R, Vangel M, Verma S, Wang J, Rossum I, Wolf D, Wolff P, Wood S, Yung A, Agurto C, Alvarez-Jimenez M, Amminger P, Armando M, Asgari-Targhi A, Cahill J, Carrión R, Castro E, Cetin-Karayumak S, Chakravarty M, Cho Y, Cotter D, D’Alfonso S, Ennis M, Fadnavis S, Fonteneau C, Gao C, Gupta T, Gur R, Gur R, Hamilton H, Hoftman G, Jacobs G, Jarcho J, Ji J, Kohler C, Lalousis P, Lavoie S, Lepage M, Liebenthal E, Mervis J, Murty V, Nicholas S, Ning L, Penzel N, Poldrack R, Polosecki P, Pratt D, Rabin R, Eichi H, Rathi Y, Reichenberg A, Reinen J, Rogers J, Ruiz-Yu B, Scott I, Seitz-Holland J, Srihari V, Srivastava A, Thompson A, Turetsky B, Walsh B, Whitford T, Wigman J, Yao B, Yuen H, Ahmed U, Byun A, Chung Y, Do K, Hendricks L, Huynh K, Jeffries C, Lane E, Langholm C, Lin E, Mantua V, Santorelli G, Ruparel K, Zoupou E, Adasme T, Addamo L, Adery L, Ali M, Auther A, Aversa S, Baek S, Bates K, Bathery A, Bayer J, Beedham R, Bilgrami Z, Birch S, Bonoldi I, Borders O, Borgatti R, Brown L, Bruna A, Carrington H, Castillo-Passi R, Chen J, Cheng N, Ching A, Clifford C, Colton B, Contreras P, Corral S, Damiani S, Done M, Estradé A, Etuka B, Formica M, Furlan R, Geljic M, Germano C, Getachew R, Goncalves M, Haidar A, Hartmann J, Jo A, John O, Kerins S, Kerr M, Kesselring I, Kim H, Kim N, Kinney K, Krcmar M, Kotler E, Lafanechere M, Lee C, Llerena J, Markiewicz C, Matnejl P, Maturana A, Mavambu A, Mayol-Troncoso R, McDonnell A, McGowan A, McLaughlin D, McIlhenny R, McQueen B, Mebrahtu Y, Mensi M, Hui C, Suen Y, Wong S, Morrell N, Omar M, Partridge A, Phassouliotis C, Pichiecchio A, Politi P, Porter C, Provenzani U, Prunier N, Raj J, Ray S, Rayner V, Reyes M, Reynolds K, Rush S, Salinas C, Shetty J, Snowball C, Tod S, Turra-Fariña G, Valle D, Veale S, Whitson S, Wickham A, Youn S, Zamorano F, Zavaglia E, Zinberg J, Woods S, Shenton M. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophrenia Bulletin 2024, 50: 496-512. PMID: 38451304, PMCID: PMC11059785, DOI: 10.1093/schbul/sbae011.Peer-Reviewed Original ResearchClinical high-risk individualsClinical high riskNational Institute of Mental HealthInstitute of Mental HealthAttenuated positive symptomsPersistent negative symptomsTransition to psychosisCHR statusHigh riskNegative symptomsPositive symptomsAnxiety symptomsPsychosocial functioningCognitive dataOutcomes of individualsDigital health technologiesDaily surveysPsychosisSCZPublic health needsMental healthNovel pharmacological interventionsSchizophreniaClinical outcomesHealth needs
2023
Effects of exercise intervention on psychotic symptoms: A meta-analysis and hypothetical model of neurobiological mechanisms
Oliva H, Monteiro-Junior R, Oliva I, Powers A. Effects of exercise intervention on psychotic symptoms: A meta-analysis and hypothetical model of neurobiological mechanisms. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2023, 125: 110771. PMID: 37075881, DOI: 10.1016/j.pnpbp.2023.110771.Peer-Reviewed Original ResearchConceptsExercise interventionGeneral symptomsPsychotic symptomsEfficacy of exerciseEffects of exerciseSpecific brain areasWeb of ScienceCochrane CENTRALSymptom improvementTemporal lobeBrain areasLarge effect sizesPsychotic patientsPositive symptomsNegative symptomsSymptomsNeurobiological mechanismsNeurophysiology studiesInterventionExerciseEffect sizeDatabase searchSignificant improvementNeurobiological modelsPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply